Ads
related to: mayo clinic aml leukemia life expectancy- AML Treatment Option
See If an AML Treatment Option
May Be Able To Help Your Patients.
- Testing For AML
Learn About The Importance of
Testing For Mutations in AML.
- View The Clinical Data
Explore The Clinical Data
For an AML Treatment Option.
- View Dosing Guidelines
Clinical Dosing Guidelines For
an AML Treatment Option.
- Physician Resources
Access Support & Resources On
The Official Physician Website.
- Clinical Recommendations
Info On a Treatment Recommendation
From An AML Treatment Guideline.
- AML Treatment Option
Search results
Results From The WOW.Com Content Network
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. [1] Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. [1]
Acute monocytic leukemia (AMoL, or AML-M5) [2] is a type of acute myeloid leukemia. In AML-M5 >80% of the leukemic cells are of monocytic lineage. [3] This cancer is characterized by a dominance of monocytes in the bone marrow. There is an overproduction of monocytes that the body does not need in the periphery.
Acute myelomonocytic leukemia (AMML) is a form of acute myeloid leukemia that involves a proliferation of CFU-GM myeloblasts and monoblasts. AMML occurs with a rapid increase amount in white blood cell count and is defined by more than 20% of myeloblast in the bone marrow.
Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally and injure various tissues. Megakaryoblasts are the most immature precursor cells in a platelet-forming lineage; they mature to promegakaryocytes and, ultimately, megakaryocytes which cells shed membrane-enclosed particles, i.e. platelets, into the circulation.
This example uses the Acute Myelogenous Leukemia survival data set "aml" from the "survival" package in R. The data set is from Miller (1997) [1] and the question is whether the standard course of chemotherapy should be extended ('maintained') for additional cycles. The aml data set sorted by survival time is shown in the box.
In aCML many clinical features (splenomegaly, myeloid predominance in the bone marrow with some dysplastic features but without a differentiation block) and laboratory abnormalities (myeloid proliferation, low leukocyte alkaline phosphatase values) suggest the diagnosis of chronic myelogenous leukemia (CML).
Ads
related to: mayo clinic aml leukemia life expectancy